-
Nursing Leaders Warn HSE Recruitment Controls Are Unsafe
-
Miranda Lambert Leads North Texans with Seven Grammy Nominations for 2027
-
Son Suk-ku and Eita Nagayama Star in Netflix’s 'The Blue Road' Cross-Border Crime Thriller
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Moving to a New State? Your Healthcare Might Get More Complicated
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
South Africa’s Economic Shift: Why Services Must Lead Job Creation Beyond Manufacturing
-
5 Strategies for Fort Worth Households to Reduce Summer Electricity Costs
-
Lethbridge Council to Vote on $80 Million Capital Improvement Program
-
Central Bank of Malta Links Energy Subsidies to Middle East Conflict and Price Volatility
-
Redmi Note 18 5G Battery Specs Leaked: Larger Capacity in Chinese Variant
-
Shomari Figures Defies Redistricting in Alabama Amid Disaster Relief Crisis
-
COP31 Presidency Publishes First Draft Cover Decision on Climate Action
-
BYD Dolphin G Leasing Deal: Plug-in Hybrid Supermini Available from £174 a Month
-
EU Club Group Files Antitrust Complaint Against UEFA Over Prize Money
-
Egypt Opens Registration for 2027 Total Solar Eclipse Viewing Packages
-
Heat and El Niño Drive Surge in Preterm Births Across Southern Africa
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Tom Brady’s Viral Reaction to Deebo Samuel’s Trick-Play Touchdown
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium
ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium.
PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer.
ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on these findings as well as earlier in vivo efficacy studies, ProteinQure has initiated GLP-toxicology studies for PQ203 in support of an anticipated investigational new drug application filing in Q2 of 2025.
"These combined findings confirm the power of our computational drug design platform and its potential to address key challenges in cancer therapy. We are deeply committed to moving PQ203 forward and are eager to bring this innovative treatment to clinical trials." stated Lucas Siow, CEO of ProteinQure.
Phase 1a/b trial initiation for PQ203 is planned for the second half of 2025 and will be coordinated at the Princess Margaret Cancer Center in Toronto and other leading hospitals in North America.
For media inquiries please contact Lucas Siow at [email protected]
SOUCE: ProteinQure Inc.
L.Meier--VB